So that is ridiculously low. And from what I saw of you last post, if I read it right, the absolute risk levels were low in the trials.

If have have this correct the targetted population for BETonMACE is patients with diebetes mellitus with CVD and low HDL. This is a large and growing population globally. The new trial will be based on a 3 point MACE measure vs 5 point from ASSURE/SUSTAIN so there is no direct comparison. That being said, in the ASSURE/SUSTAIN trials with DM, CVD with low HDL after 210 days the absolute risk was 21% in the control group (Crestor only) and approx 5% in the Crestor + rvx-208 group for an RRR of approx 77% which I think had a p<.02 (highly significant).

So the achievements of Jardiance seem pretty small at face value.

Again, why does the RVX share price perform so poorly. It is shockingly low. NASDAQ is a key issue.

Thanks.

Toinv